Gastroenterology and Hepatology Research Studies
The OHSU Division of Gastroenterology and Hepatology's Research Team provides expertise in clinical research. We conduct research studies for various gastrointestinal and hepatic conditions. Most trials have a limited number of spots or time allowed to enroll patients.
Currently Enrolling Trials
Abdominal Wall Injections for Abdominal Pain
Title: Effect of Abdominal Wall Injections on Abdominal Pain
Goal: The goal of the study is to determine the effect of abdominal wall injections on abdominal pain.
Who is Eligible: Patients with abdominal wall pain receiving an injection of lidocaine for abdominal wall pain.
Principal Investigator: Sophia Lichenstein-Hill, D.N.P.
Bowel Strictures
PATENT-B
Title: Paclitaxel Coated balloon for the Treatment of chronic bEnigN sTricture-Bowel (PATENT-B)
Goal: This study is being conducted to see whether GIE Medical’s new ProTractX3™ TTS drug coated balloon can treat recurrent benign bowel strictures and reduce the rate of recurrence.
Who is Eligible: Patients with a diagnosis of a benign bowel stricture with at least 2 previous dilations.
Principal Investigator: Jessica Yu, M.D., M.S.
Checkpoint Inhibitor Colitis and Hepatitis
Title: Dissecting Immune Mechanisms of Colitis and Hepatitis that Occurs in Patients on Immune Checkpoint Inhibitor Therapy (anti-PD-1, anti-PD-L1, and/or anti CTLA-4) for Cancer
Goal: The goal of this research is to understand the basic immune mechanisms that cause inflammatory colitis and hepatitis associated with immune checkpoint inhibitors and the factors that predict which patients are likely to develop these immune toxicities.
Who is Eligible: Patients aged 18-80 who are on checkpoint inhibitors or are about to start them.
Principal Investigator: Molly Thomas, M.D., Ph.D.
Website: https://www.ohsu.edu/school-of-medicine/thomas-lab/projects
Colorectal Cancer Biomarkers
GLNE
Study Title: Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
Goal: The goal of this study if to determine if stool or blood can be used to detect colon cancers as early or earlier than colonoscopy.
Who is Eligible: Patients scheduled for a colonoscopy for colon cancer surveillance, or patients with colon cancer who have not yet had surgery, chemotherapy or radiation.
Principal Investigator: Seth Crockett, M.D., M.P.H.
Website: https://classic.clinicaltrials.gov/ct2/show/NCT00843375
Colorectal Cancer Screening
FORTE
Study Title: Five or Ten-Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Goal: The goal of this study is to determine the appropriate surveillance for patients who have 1-2 small benign polyps (adenomatous polyps/adenomas) removed during colonoscopy.
Who is Eligible: Patients ages 45-70, with a first-time diagnosis of 1-2 non-advanced polyps removed by colonoscopy.
Principal Investigator: Seth Crockett, M.D., M.P.H.
Website: https://www.nrgoncology.org/FORTE
COOP
Study Title: Colonoscopy versus Stool-based Testing for Older Adults with a History of Colon Polyps
Goal: The goal of this study is to compare the effectiveness of annual fecal immunochemical testing (FIT) vs colonoscopy in adults ages 65-82 with history of low-risk colorectal polyps.
Who is Eligible: Patients ages 65-82, with 1-2 non-advanced polyps on their most recent colonoscopy OR personal history of colorectal polyps (≥1 lifetime adenoma, sessile serrated polyp).
Principal Investigator: Seth Crockett, M.D., M.P.H.
Esophageal Strictures
PATENT-E
Title: Paclitaxel Coated Balloon for the Treatment of Chronic Benign Stricture - Esophagus
Goal: This study is being conducted to see whether GIE Medical’s new ProTractX3™ TTS drug coated balloon can treat esophageal strictures and reduce the rate of recurrence.
Who is Eligible: Patients with a diagnosis of a benign esophageal stricture with at least 2 previous dilations.
Principal Investigator: Fouad Otaki, M.D.
Fecal Microbiota Transplant
FMT National Registry
Title: Fecal Microbiota Transplant National Registry
Goal: The goal of the research is to understand the safety and effectiveness of fecal microbiota transplant as a treatment for C. diff and other health conditions, as well as its impact on patients over the years.
Who is Eligible: Patients receiving FMT or other gut-related-microbiota products.
Principal Investigator: Melissa Hershman, M.D., B.S.N.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Title: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Patient Registry
Goal: To monitor trends in patient risk and outcomes and the impact of healthcare practices and interventions.
Who is Eligible: Patients age 18-99 with a diagnosis of MASLD who are seen at the OHSU MASLD clinic for evaluation or follow-up.
Principal Investigator: Manida Wungjiranirun, M.D.
Pancreatic Cysts
EA2185
Study Title: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Goal: The goal of this study is to determine if biomarkers from blood and imaging predict the development of worrisome features or signs of pancreatic cancer.
Who is Eligible: Patients ages 50-75 with a pancreatic cyst ≥ 1 cm with imaging (CT, MRI, or EUS) in the past 6 months.
Principal Investigator: Kaveh Sharzehi, M.D., M.S.
Website: https://ecog-acrin.org/clinical-trials/ea2185-pancreas-cancer-preventio…
Pancreatic Cancer Screening
PCDC
Title: Validation of Novel Imaging and Molecular Tests for Early Detection of Pancreatic Cancer through Risk-stratified Community Engagement Programs
Goal: The goal of this study is to evaluate the dynamics of blood and imaging biomarkers for pancreatic cancer in high-risk patients
Who is Eligible: Patients undergoing MRI/MRCP for either (1) a known diagnosis of chronic pancreatitis, (2) abdominal pain without a known history of pancreatitis, but with a concomitant diagnosis of diabetes, (3) patients with a suspected diagnosis of intraductal papillary mucinous neoplasms (IPMN), and (4) patients with a known or suspected diagnosis of pancreatic ductal adenocarcinoma (PDAC). Healthy volunteers will also be recruited as a comparison group.
Principal Investigator: Gregory Cote, M.D., M.S.